Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma.
- Creators
- Decaens, Thomas
- Roudot-Thoraval, Françoise
- Badran, Hanaa
- Wolf, Philippe
- Durand, François
- Adam, Rene
- Boillot, Olivier
- Vanlemmens, Claire
- Gugenheim, Jean
- Dharancy, Sébastien
- Bernard, Pierre-Henri
- Boudjema, Karim
- Calmus, Yvon
- Hardwigsen, Jean
- Ducerf, Christian
- Pageaux, Georges Philippe
- Hilleret, Marie-Noelle
- Chazouillères, Olivier
- Cherqui, Daniel
- Mallat, Ariane
- Duvoux, Christophe
- Others:
- Institut Mondor de Recherche Biomédicale (IMRB) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- Service de santé publique [Mondor] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
- Service de Chirurgie Générale et Transplantation Multi Organes ; CHU Strasbourg
- Chercheur indépendant
- Rythmes Biologiques et Cancers ; Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Service d'anatomie pathologique ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse
- Unité de chronothérapie ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse
- Centre méditerranéen de médecine moléculaire (C3M) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)
- Département Digestif ; Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital de l'Archet
- Service d'Hépato-Gastro-Entérologie ; CHU Bordeaux [Bordeaux]-Hôpital Saint-André
- Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes] ; CHU Pontchaillou [Rennes]
- Foie, métabolismes et cancer ; Université de Rennes 1 (UR1) ; Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Service de Chirurgie Digestive ; Hôpital Cochin [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Service de Chirurgie ; Assistance Publique - Hôpitaux de Marseille (APHM)-Hospices Civiles de Marseille-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION)
- Département de Gastroentérologie et hépatologie ; Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon
- Service de chirurgie digestive ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor
- Service d'hépato-gastro-entérologie [APHP Henri Mondor] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
Description
AIM: To generate a new score with improved accuracy compared with Milan criteria to select patients. PATIENTS: The training cohort comprised 373 patients transplanted for hepatocellular carcinoma (HCC) between 1988 and 1998 (cohort 1). An algorithm was derived from the analysis of patient data by the proportional hazard Cox regression model. The area under the receiver operating characteristic (AUROC) was used to determine a cut-off value. The validation cohort comprised 140 patients transplanted between 1999 and 2001 (cohort 2). RESULTS: Multivariate analysis identified three predictors of 5-year tumour-free survival: tumour differentiation (P=0.02), diameter (P<0.0001) and number of nodules (P=0.04). A cut-off value of 4 was derived from the AUROC of the final score. Five-year tumour-free survival was 60.2 ± 3.1% in patients with as score <4 and 36.4 ± 4.7% in individuals with a score ≥4, P<0.0001. In the validation cohort, 5-year tumour-free survival was 82.8 ± 3.6% (score <4) and 50.0 ± 10.7% (score ≥4), P=0.0003. In patients with a score <4, there was no significant difference in 5-year tumour-free survival between Milan+ and Milan- patients, either in cohort 1 or 2. Five-year tumour-free survival of Milan- patients was significantly better in individuals with a score <4 compared with those with a score ≥4, both in cohort 1 (61.5 ± 9.1 vs 31.4 ± 4.6%, P=0.009) and in cohort 2 (P=0.02). CONCLUSION: A novel score taking into account tumour differentiation shows higher accuracy than Milan criteria in predicting 5-year tumour-free survival following liver transplantation for HCC. Prospective studies should validate these findings.
Abstract
International audience
Additional details
- URL
- https://hal.archives-ouvertes.fr/hal-00739491
- URN
- urn:oai:HAL:hal-00739491v1
- Origin repository
- UNICA